- Home
- ESEA vs PGEN Comparison
ESEA vs PGEN Comparison
Compare ESEA & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESEA | PGEN |
|---|---|---|
| Founded | 2005 | 1998 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.2M | 1.4B |
| IPO Year | 2005 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ESEA | PGEN |
|---|---|---|
| Price | $70.43 | $4.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $62.00 | $8.33 |
| AVG Volume (30 Days) | 43.6K | ★ 2.9M |
| Earning Date | 06-17-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.24% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | $1.74 | $1,115.92 |
| Revenue Next Year | $1.07 | $81.04 |
| P/E Ratio | $3.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $37.40 | $1.28 |
| 52 Week High | $74.76 | $5.47 |
Technical Indicators
Market Signals| Indicator | ESEA | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 51.73 | 53.54 |
| Support Level | $52.02 | $3.97 |
| Resistance Level | $73.31 | $4.40 |
| Average True Range (ATR) | 3.40 | 0.24 |
| MACD | -0.46 | -0.01 |
| Stochastic Oscillator | 54.85 | 34.78 |
Price Performance
Historical ComparisonAbout ESEA Euroseas Ltd. (Marshall Islands)
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.
About PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.